Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Silver
They are different routes to the same goal. They both end up in a clinical trial. The CTN route can be used where there is adequate preclinical information available. The CTA route is for higher risk or novel trials.
You can read all the blurb here:
https://www.tga.gov.au/resources/which-clinical-trial-scheme-should-i-choose
LH&K
Mafuta
I found it interesting that SAR has gone for a CTN and not a CTA. Here is what I found on the regulator's website:
"The CTN scheme may be used for earlier phase studies if there is adequate preclinical information available, especially regarding safety. The CTA route is generally for high risk or novel treatments, such as gene therapy, where there is no or limited knowledge of safety."
It would appear then that the BOD is confident of the preclinical evidence they have so far to satisfy the CTN route ... Importantly the CTN is a much faster route.
LH&K Mafuta
https://www.edisongroup.com/research/sdc-1801-trial-application-refiled-in-australia/32087/
https://twitter.com/Sareumplc/status/1635938898093252609?t=R2XU4dep9UGImWulznjSrw&s=19
Further clarity requested by Sareum from the UK Medicines and Healthcare Products Regulatory Authority (MHRA) regarding its original clinical trial authorisation application has not been received. Shocking really ... LH&K Mafuta
Cambridge, UK, 15 March 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces today that it has initiated an application to perform Phase 1 clinical studies on SDC-1801 in Australia under the Clinical Trial Notification (CTN) scheme.
Rather than adding to a market's store of useful information, short-and-distort traders pollute it with false claims in an effort to provoke shareholders to sell, driving the share price lower. As with other market manipulation schemes, short-and-distort often uses social media, taking advantage of the anonymity it offers and the ease with which misleading claims can spread online.
https://www.investopedia.com/articles/analyst/030102.asp#:~:text=Short%2Dand%2Ddistort%20is%20an,to%20drive%20down%20its%20price.
LH&K Mafuta
Ah ... "the man on the Clapham omnibus" ... now thats a fine legal precedent ... almost as compelling as the "duck" test ... the fact is that people have been taken to task by companies who's share prices have been adversely affected by malicious statements ... LH&K Mafuta
Interestingly, Toth (I think), predicted that we would see the emergence of a more sophisticated and sinister type of poster as we get closer to the goal ... I find their efforts rather entertaining. LH&K Mafuta
https://twitter.com/Sareumplc/status/1633064483638632450?t=1KXQaBG7CwNqW39xU5otDw&s=19
Today's RNS was simply confirmation of something we knew . Now the BOD have the data they can analyse it and formulate a way forward. Meanwhile back at the ranch they are desperately trying to get our lead asset 1801 in to trials. I would suggest our BOD have rather a lot on their plate at the moment. LH7K Mafuta
Sadly I share the tragic results of Cancer. Lost two brothers and countless friends to various kinds. My daughter in law's mother has terminal cancer too. My thoughts go out to all who suffer and those that may wonder if they are next. The sooner we manage to conquer this scourge the better. LH&K Mafuta